Cipher Pharmaceuticals is forecast to grow earnings and revenue by 12.7% and 18.8% per annum respectively. EPS is expected to grow by 13.4% per annum. Return on equity is forecast to be 14.2% in 3 years.
Key information
12.7%
Earnings growth rate
13.4%
EPS growth rate
Pharmaceuticals earnings growth
18.5%
Revenue growth rate
18.8%
Future return on equity
14.2%
Analyst coverage
Low
Last updated
08 Nov 2024
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
DB:PHE - Analysts future estimates and past financials data (USD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2026
55
25
N/A
35
2
12/31/2025
50
23
N/A
26
3
12/31/2024
34
14
N/A
18
3
9/30/2024
26
16
-67
13
N/A
6/30/2024
22
23
17
17
N/A
3/31/2024
22
23
14
14
N/A
12/31/2023
21
20
16
16
N/A
9/30/2023
21
32
15
15
N/A
6/30/2023
20
28
13
13
N/A
3/31/2023
20
27
13
13
N/A
12/31/2022
21
27
11
11
N/A
9/30/2022
22
10
15
15
N/A
6/30/2022
21
8
11
11
N/A
3/31/2022
22
9
11
11
N/A
12/31/2021
22
8
14
14
N/A
9/30/2021
22
5
14
14
N/A
6/30/2021
23
6
12
12
N/A
3/31/2021
21
3
11
11
N/A
12/31/2020
22
4
11
12
N/A
9/30/2020
21
7
7
7
N/A
6/30/2020
22
3
10
11
N/A
3/31/2020
23
4
11
12
N/A
12/31/2019
22
3
7
8
N/A
9/30/2019
23
-1
6
8
N/A
6/30/2019
22
2
4
6
N/A
3/31/2019
23
3
0
2
N/A
12/31/2018
23
1
1
8
N/A
9/30/2018
28
6
7
13
N/A
6/30/2018
34
9
N/A
18
N/A
3/31/2018
37
11
N/A
19
N/A
12/31/2017
40
11
N/A
13
N/A
9/30/2017
34
7
N/A
11
N/A
6/30/2017
32
5
N/A
9
N/A
3/31/2017
31
1
N/A
10
N/A
12/31/2016
30
4
N/A
11
N/A
9/30/2016
33
6
N/A
8
N/A
6/30/2016
34
2
N/A
7
N/A
3/31/2016
34
1
N/A
7
N/A
12/31/2015
34
2
N/A
8
N/A
9/30/2015
32
3
N/A
12
N/A
6/30/2015
30
13
N/A
16
N/A
3/31/2015
30
18
N/A
19
N/A
12/31/2014
29
19
N/A
25
N/A
9/30/2014
33
31
N/A
23
N/A
6/30/2014
32
27
N/A
18
N/A
3/31/2014
29
25
N/A
15
N/A
12/31/2013
25
24
N/A
7
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHE's forecast earnings growth (12.7% per year) is above the savings rate (1%).
Earnings vs Market: PHE's earnings (12.7% per year) are forecast to grow slower than the German market (20.7% per year).
High Growth Earnings: PHE's earnings are forecast to grow, but not significantly.
Revenue vs Market: PHE's revenue (18.8% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: PHE's revenue (18.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PHE's Return on Equity is forecast to be low in 3 years time (14.2%).